Biogen Resurrects Alzheimer’s Drug for FDA Approval

Drug Industry Daily
A A
Biogen has decided to renew its bid for FDA approval in early 2020 of its investigational anti-amyloid Alzheimer’s drug aducanumab after halting clinical trials earlier this year.

To View This Article:

Login

Subscribe To Drug Industry Daily